Browse Studies — Arctuva

Phase 2

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-…

Primary Progressive Multiple SclerosisPrimary Progressive MSPrimary Progressive Multiple Sclerosis (PPMS)+6 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.